Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: A review

International Journal of Clinical Practice

Volumn 63, Issue 5, 2009, Pages 799-805

  Kurz, A ^a   Farlow, M ^b   Lefevre G ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INDIANA UNIVERSITY   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RIVASTIGMINE;

ALZHEIMER DISEASE; APPLICATION SITE ERYTHEMA; ARTICLE; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG METABOLISM; ENZYME INHIBITION; FOOD; FOOD DRUG INTERACTION; HUMAN; MAXIMUM PLASMA CONCENTRATION; NAUSEA AND VOMITING; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; ALZHEIMER DISEASE; BIOLOGICAL AVAILABILITY; CHOLINESTERASE INHIBITORS; HUMANS; PHENYLCARBAMATES; TREATMENT OUTCOME;

EID: 64149090366     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02052.x     Document Type: Article

References (20)

1. Cutler NR, Polinsky RJ, Sramek JJ et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. Acta Neurol Scand 1998 97 : 244 50.
2. Imbimbo BP. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs 2001 15 : 375 90.
3. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998 1 : 55 65.
4. Rösler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999 318 : 633 8.
5. Schneider LS, Anand R, Farlow MR. Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease. Int J Geriatr Psychopharmacol 1998 1 (Suppl. 1 S26 34.
6. Cummings J, Lefèvre G, Small G, Appel-Dingemanse S. Pharmacokinetic rationale for the rivastigmine patch. Neurology 2007 69 (4 Suppl. 1 S10 3.
7. Blesa R, Ballard C, Orgogozo J-M, Lane R, Thomas S. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Neurology 2007 69 (Suppl. 1 S23 8.
8. WIPO (WO-2008-021113). Transdermal methods and systems for treating Alzheimer's disease. http://www.wipo.int/pctdb/en/wo.jsp?WO=2008021113 (accessed March 2009).
9. Feldman HH, Lane R. Rivastigmine: a placebo-controlled trial of BID and TID regimens in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2007 78 : 1056 63.
10. Zhao Q, Jannssens L, Verhaeghe T, Brashear HR, Truyen L. Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers. Curr Med Res Opin 2005 21 : 1547 54.
11. Nitti VW, Sanders S, Staskin DR et al. Transdermal delivery of drugs for urologic applications: basic principles and applications. Urology 2006 67 : 657 64.
12. Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 2000 9 : 165 9.
13. Lefèvre G, Sdek G, Jhee S et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin Pharmacol Ther 2008 83 : 106 14.
14. Smith BP, Vandenhende FR, DeSante KA et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res 2000 17 : 1278 83.
15. Mercier F, Lefèvre G, Huang HL, Schmidli H, Amzal B, Dingemanse SA. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin 2007 23 : 3199 204.
16. Lefèvre G, Pommier F, Sdek G et al. Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects. J Clin Pharmacol 2008 48 : 246 52.
17. Lefèvre G, Sdek G, Huang HL et al. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J Clin Pharmacol 2007 47 : 471 8.
18. Spencer CM, Noble S. Rivastigmine. A review of its use in Alzheimer's disease. Drugs Aging 1998 13 : 391 411.
19. Winblad B, Cummings J, Andreasen N et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007 22 : 456 67.
20. Winblad B, Machado JC. Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease. Expert Opin Drug Deliv 2008 5 : 1377 86.